help button home button
AJRCCM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by DOUGLAS, W. W.
Right arrow Articles by SCHROEDER, D. R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by DOUGLAS, W. W.
Right arrow Articles by SCHROEDER, D. R.

Am. J. Respir. Crit. Care Med., Volume 161, Number 4, April 2000, 1172-1178

Idiopathic Pulmonary Fibrosis
Impact of Oxygen and Colchicine, Prednisone, or No Therapy on Survival

WILLIAM W. DOUGLAS, JAY H. RYU, and DARRELL R. SCHROEDER

Division of Pulmonary and Critical Care Medicine and Section of Biostatistics, Mayo Clinic, Rochester, Minnesota

The clinical records of 487 patients seen at Mayo Clinic Rochester (MCR) during 1994 through 1996 who were diagnosed as having idiopathic pulmonary fibrosis of the usual interstitial pneumonia type (IPF/UIP) were reviewed. Computed tomography (CT) had been done in 94.7% of patients and surgical open lung biopsy (OLB) in 20.3%. Median survival was 3.2 yr. We compared survival as a function of treatment program, based on intent to treat at the time of the initial contact within the study window. Treatment advised included colchicine alone in 167, no therapy in 157, prednisone at maintenance dosages alone in 54, colchicine plus prednisone in 71, and other programs in 38. Oxygen therapy was advised in 133 patients. By univariate analysis, worse survival was associated with prednisone therapy compared with no therapy, and with oxygen therapy compared with no oxygen therapy. However, on multivariate analysis, worse survival was associated with older age, male gender, lower diffusing capacity for carbon monoxide (DLCO), lower alveolar volume (VA), and a history of worsening pulmonary function. When adjustment was made for these factors, there was no significant difference in survival between those patients treated with colchicine or prednisone and those on no therapy, and no difference between those on oxygen therapy and those without oxygen.




This article has been cited by other articles:


Home page
 Therapeutic Advances in Respiratory DiseaseHome page
R. Kim and K. C. Meyer
Review: Therapies for interstitial lung disease: past, present and future
Therapeutic Advances in Respiratory Disease, October 1, 2008; 2(5): 319 - 338.
[Abstract] [PDF]

Home page
 ThoraxHome page
A U Wells, N Hirani, and on behalf of the BTS Interstitial Lung Disease Gui
Interstitial lung disease guideline
Thorax, September 1, 2008; 63(Suppl_5): v1 - v58.
[Full Text] [PDF]

Home page
 RadiologyHome page
A. C. Best, J. Meng, A. M. Lynch, C. M. Bozic, D. Miller, G. K. Grunwald, and D. A. Lynch
Idiopathic Pulmonary Fibrosis: Physiologic Tests, Quantitative CT Indexes, and CT Visual Scores as Predictors of Mortality
Radiology, March 1, 2008; 246(3): 935 - 940.
[Abstract] [Full Text] [PDF]

Home page
 ChestHome page
R. Hyzy, S. Huang, J. Myers, K. Flaherty, and F. Martinez
Acute Exacerbation of Idiopathic Pulmonary Fibrosis
Chest, November 1, 2007; 132(5): 1652 - 1658.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Respir. Crit. Care Med.Home page
I. O. Rosas, P. Ren, N. A. Avila, C. K. Chow, T. J. Franks, W. D. Travis, J. P. McCoy Jr., R. M. May, H.-P. Wu, D. M. Nguyen, et al.
Early Interstitial Lung Disease in Familial Pulmonary Fibrosis
Am. J. Respir. Crit. Care Med., October 1, 2007; 176(7): 698 - 705.
[Abstract] [Full Text] [PDF]

Home page
 ChestHome page
D. S. Ayo, G. L. Aughenbaugh, E. S. Yi, J. L. Hand, and J. H. Ryu
Cystic Lung Disease in Birt-Hogg-Dube Syndrome
Chest, August 1, 2007; 132(2): 679 - 684.
[Abstract] [Full Text] [PDF]

Home page
 ChestHome page
M. Alakhras, P. A. Decker, H. F. Nadrous, M. Collazo-Clavell, and J. H. Ryu
Body Mass Index and Mortality in Patients With Idiopathic Pulmonary Fibrosis
Chest, May 1, 2007; 131(5): 1448 - 1453.
[Abstract] [Full Text] [PDF]

Home page
 ChestHome page
J. G. Parambil, J. L. Myers, R. M. Lindell, E. L. Matteson, and J. H. Ryu
Interstitial lung disease in primary sjogren syndrome.
Chest, November 1, 2006; 130(5): 1489 - 1495.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Pathol.Home page
H. Yasuoka, Z. Zhou, J. M. Pilewski, T. D. Oury, A. M.K. Choi, and C. A. Feghali-Bostwick
Insulin-Like Growth Factor-Binding Protein-5 Induces Pulmonary Fibrosis and Triggers Mononuclear Cellular Infiltration
Am. J. Pathol., November 1, 2006; 169(5): 1633 - 1642.
[Abstract] [Full Text] [PDF]

Home page
 Eur Respir JHome page
G. Raghu
Idiopathic pulmonary fibrosis: treatment options in pursuit of evidence-based approaches.
Eur. Respir. J., September 1, 2006; 28(3): 463 - 465.
[Full Text] [PDF]

Home page
 Eur Respir JHome page
K. M. Antoniou, A. G. Nicholson, M. Dimadi, K. Malagari, P. Latsi, A. Rapti, N. Tzanakis, R. Trigidou, V. Polychronopoulos, and D. Bouros
Long-term clinical effects of interferon gamma-1b and colchicine in idiopathic pulmonary fibrosis
Eur. Respir. J., September 1, 2006; 28(3): 496 - 504.
[Abstract] [Full Text] [PDF]

Home page
 ChestHome page
J. G. Parambil, J. L. Myers, and J. H. Ryu
Diffuse alveolar damage: uncommon manifestation of pulmonary involvement in patients with connective tissue diseases.
Chest, August 1, 2006; 130(2): 553 - 558.
[Abstract] [Full Text] [PDF]

Home page
 Proc Am Thorac SocHome page
N. Walter, H. R. Collard, and T. E. King Jr.
Current perspectives on the treatment of idiopathic pulmonary fibrosis.
Proceedings of the ATS, January 1, 2006; 3(4): 330 - 338.
[Abstract] [Full Text] [PDF]

Home page
 ChestHome page
J. G. Parambil, J. L. Myers, and J. H. Ryu
Histopathologic Features and Outcome of Patients With Acute Exacerbation of Idiopathic Pulmonary Fibrosis Undergoing Surgical Lung Biopsy
Chest, November 1, 2005; 128(5): 3310 - 3315.
[Abstract] [Full Text] [PDF]

Home page
 Eur Respir JHome page
D. Bouros and K. M. Antoniou
Current and future therapeutic approaches in idiopathic pulmonary fibrosis
Eur. Respir. J., October 1, 2005; 26(4): 693 - 703.
[Abstract] [Full Text] [PDF]

Home page
 ChestHome page
L. Tiitto, U. Heiskanen, R. Bloigu, P. Paakko, V. Kinnula, and R. Kaarteenaho-Wiik
Thoracoscopic Lung Biopsy Is a Safe Procedure in Diagnosing Usual Interstitial Pneumonia
Chest, October 1, 2005; 128(4): 2375 - 2380.
[Abstract] [Full Text] [PDF]

Home page
 ChestHome page
H. F. Nadrous, P. A. Pellikka, M. J. Krowka, K. L. Swanson, N. Chaowalit, P. A. Decker, and J. H. Ryu
Pulmonary Hypertension in Patients With Idiopathic Pulmonary Fibrosis
Chest, October 1, 2005; 128(4): 2393 - 2399.
[Abstract] [Full Text] [PDF]

Home page
 The Annals of PharmacotherapyHome page
M. A Pacanowski and G. W Amsden
Interferon Gamma-1b in the Treatment of Idiopathic Pulmonary Fibrosis
Ann. Pharmacother., October 1, 2005; 39(10): 1678 - 1686.
[Abstract] [Full Text] [PDF]

Home page
 ChestHome page
E. K. Bajwa, N. T. Ayas, M. Schulzer, E. Mak, J. H. Ryu, and A. Malhotra
Interferon-{gamma}1b Therapy in Idiopathic Pulmonary Fibrosis: A Metaanalysis
Chest, July 1, 2005; 128(1): 203 - 206.
[Abstract] [Full Text] [PDF]

Home page
 ChestHome page
H.-L. Lee, J. H. Ryu, M. H. Wittmer, T. E. Hartman, J. F. Lymp, H. D. Tazelaar, and A. H. Limper
Familial Idiopathic Pulmonary Fibrosis: Clinical Features and Outcome
Chest, June 1, 2005; 127(6): 2034 - 2041.
[Abstract] [Full Text] [PDF]

Home page
 Eur Respir JHome page
K. A. Keogh, J. Standing, G. C. Kane, A. Terzic, and A. H. Limper
Angiotensin II antagonism fails to ameliorate bleomycin-induced pulmonary fibrosis in mice
Eur. Respir. J., April 1, 2005; 25(4): 708 - 714.
[Abstract] [Full Text] [PDF]

Home page
 ChestHome page
J. H. Ryu, J. L. Myers, S. A. Capizzi, W. W. Douglas, R. Vassallo, and P. A. Decker
Desquamative Interstitial Pneumonia and Respiratory Bronchiolitis-Associated Interstitial Lung Disease
Chest, January 1, 2005; 127(1): 178 - 184.
[Abstract] [Full Text] [PDF]

Home page
 ChestHome page
J. J. Swigris, W. G. Kuschner, J. L. Kelsey, and M. K. Gould
Idiopathic Pulmonary Fibrosis: Challenges and Opportunities for the Clinician and Investigator
Chest, January 1, 2005; 127(1): 275 - 283.
[Abstract] [Full Text] [PDF]

Home page
 ChestHome page
J. J. Swigris, M. K. Gould, and S. R. Wilson
Health-Related Quality of Life Among Patients With Idiopathic Pulmonary Fibrosis
Chest, January 1, 2005; 127(1): 284 - 294.
[Abstract] [Full Text] [PDF]

Home page
 ChestHome page
H. F. Nadrous, J. H. Ryu, W. W. Douglas, P. A. Decker, and E. J. Olson
Impact of Angiotensin-Converting Enzyme Inhibitors and Statins on Survival in Idiopathic Pulmonary Fibrosis
Chest, August 1, 2004; 126(2): 438 - 446.
[Abstract] [Full Text] [PDF]

Home page
 CMAJHome page
N. Khalil and R. O'Connor
Idiopathic pulmonary fibrosis: current understanding of the pathogenesis and the status of treatment
Can. Med. Assoc. J., July 20, 2004; 171(2): 153 - 160.
[Abstract] [Full Text] [PDF]

Home page
 ChestHome page
H. R. Collard, J. H. Ryu, W. W. Douglas, M. I. Schwarz, D. Curran-Everett, T. E. King Jr., and K. K. Brown
Combined Corticosteroid and Cyclophosphamide Therapy Does Not Alter Survival in Idiopathic Pulmonary Fibrosis
Chest, June 1, 2004; 125(6): 2169 - 2174.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Pathol.Home page
C Jakubzick, E S Choi, S L Kunkel, H Evanoff, F J Martinez, R K Puri, K R Flaherty, G B Toews, T V Colby, E A Kazerooni, et al.
Augmented pulmonary IL-4 and IL-13 receptor subunit expression in idiopathic interstitial pneumonia
J. Clin. Pathol., May 1, 2004; 57(5): 477 - 486.
[Abstract] [Full Text] [PDF]

Home page
 Asian Cardiovasc. Thorac. Ann.Home page
M. Yamaguchi, I. Yoshino, R. Suemitsu, A. Osoegawa, T. Kameyama, T. Tagawa, S. Fukuyama, and Y. Maehara
Elective Video-Assisted Thoracoscopic Lung Biopsy for Interstitial Lung Disease
Asian Cardiovasc Thorac Ann, March 1, 2004; 12(1): 65 - 68.
[Abstract] [Full Text] [PDF]

Home page
 NEJMHome page
G. Raghu, K. K. Brown, W. Z. Bradford, K. Starko, P. W. Noble, D. A. Schwartz, T. E. King Jr., and the Idiopathic Pulmonary Fibrosis Study Group
A Placebo-Controlled Trial of Interferon Gamma-1b in Patients with Idiopathic Pulmonary Fibrosis
N. Engl. J. Med., January 8, 2004; 350(2): 125 - 133.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Respir. Crit. Care Med.Home page
V. N. Lama, K. R. Flaherty, G. B. Toews, T. V. Colby, W. D. Travis, Q. Long, S. Murray, E. A. Kazerooni, B. H. Gross, J. P. Lynch III, et al.
Prognostic Value of Desaturation during a 6-Minute Walk Test in Idiopathic Interstitial Pneumonia
Am. J. Respir. Crit. Care Med., November 1, 2003; 168(9): 1084 - 1090.
[Abstract] [Full Text] [PDF]

Home page
 ChestHome page
D. W. Kamp
Idiopathic Pulmonary Fibrosis: The Inflammation Hypothesis Revisited
Chest, October 1, 2003; 124(4): 1187 - 1190.
[Full Text] [PDF]

Home page
 Am. J. Respir. Crit. Care Med.Home page
S. Shimizu, E. C. Gabazza, O. Taguchi, H. Yasui, Y. Taguchi, T. Hayashi, M. Ido, T. Shimizu, T. Nakagaki, H. Kobayashi, et al.
Activated Protein C Inhibits the Expression of Platelet-derived Growth Factor in the Lung
Am. J. Respir. Crit. Care Med., May 15, 2003; 167(10): 1416 - 1426.
[Abstract] [Full Text] [PDF]

Home page
 Arch Intern MedHome page
H. R. Collard and T. E. King Jr
Demystifying Idiopathic Interstitial Pneumonia
Arch Intern Med, January 13, 2003; 163(1): 17 - 29.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Respir. Crit. Care Med.Home page
R. G. Crystal, P. B. Bitterman, B. Mossman, M. I. Schwarz, D. Sheppard, L. Almasy, H. A. Chapman, S. L. Friedman, T. E. King Jr., L. A. Leinwand, et al.
Future Research Directions in Idiopathic Pulmonary Fibrosis: Summary of a National Heart, Lung, and Blood Institute Working Group
Am. J. Respir. Crit. Care Med., July 15, 2002; 166(2): 236 - 246.
[Abstract] [Full Text] [PDF]

Home page
 Eur Respir JHome page
K.R. Flaherty, G.B. Toews, W.D. Travis, T.V. Colby, E.A. Kazerooni, B.H. Gross, A. Jain, R.L. Strawderman III, R. Paine, A. Flint, et al.
Clinical significance of histological classification of idiopathic interstitial pneumonia
Eur. Respir. J., February 1, 2002; 19(2): 275 - 283.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Respir. Crit. Care Med.Home page
M. J. TOBIN
Tuberculosis, Lung Infections, and Interstitial Lung Disease in AJRCCM 2000
Am. J. Respir. Crit. Care Med., November 15, 2001; 164(10): 1774 - 1788.
[Full Text] [PDF]

Home page
 Am. J. Respir. Crit. Care Med.Home page
W. W. DOUGLAS, H. D. TAZELAAR, T. E. HARTMAN, R. P. HARTMAN, P. A. DECKER, D. R. SCHROEDER, and J. H. RYU
Polymyositis-Dermatomyositis-associated Interstitial Lung Disease
Am. J. Respir. Crit. Care Med., October 1, 2001; 164(7): 1182 - 1185.
[Abstract] [Full Text] [PDF]

Home page
 NEJMHome page
T. J. Gross and G. W. Hunninghake
Idiopathic Pulmonary Fibrosis
N. Engl. J. Med., August 16, 2001; 345(7): 517 - 525.
[Full Text] [PDF]

Home page
 ChestHome page
M. Selman
Idiopathic Pulmonary Fibrosis Challenges for the Future
Chest, July 1, 2001; 120(1): 8 - 10.
[Full Text] [PDF]

Home page
 Eur Respir JHome page
J.P. Utz, J.H. Ryu, W.W. Douglas, T.E. Hartman, H.D. Tazelaar, J.L. Myers, M.S. Allen, and D.R. Schroeder
High short-term mortality following lung biopsy for usual interstitial pneumonia
Eur. Respir. J., February 1, 2001; 17(2): 175 - 179.
[Abstract] [Full Text] [PDF]

Home page
 ANN INTERN MEDHome page
M. Selman, T. E. King Jr., and A. Pardo
Idiopathic Pulmonary Fibrosis: Prevailing and Evolving Hypotheses about Its Pathogenesis and Implications for Therapy
Ann Intern Med, January 16, 2001; 134(2): 136 - 151.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Proc. Am. Thorac. Soc. Am. J. Respir. Cell Mol. Biol.
Copyright © 2000 American Thoracic Society 		  ATS State of the Art 2009